Calibrations Demand Radnostix offers a full line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems, indicating recurring potential sales opportunities for precision calibration products and associated service contracts.

Theranostics Fuel With involvement in radioisotope production and radioisotope API supply for theranostics, there are cross-sell opportunities to expand into related radiopharmaceuticals, regulatory-compliant APIs, and custom manufacturing for clinical and research collaborations.

Device Acquisition The Lucerno Dynamics asset acquisition adds LARA system technology and dosimetry-focused software, presenting upsell potential to healthcare facilities for IV radiopharmaceutical dosimetry optimization and extravasation reduction solutions.

Supply Resilience Recent recall actions and isotope supply disruptions highlight a buyer need for reliable isotopes, alternative sourcing, and expanded buffer inventories, creating opportunities to position Radnostix as a trusted supplier and risk‑mitigation partner.

Strategic Growth FY2025 revenue achievement shows momentum in calibration and reference products with ongoing product launches, suggesting scalable opportunities in medical imaging centers, nuclear pharmacies, and industrial clients seeking standardized radiopharmaceutical support.